Combating psychosis in Parkinson’s disease patients: the use of antipsychotic drugs

Author： Chou Kelvin L   Fernandez Hubert H  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.15, Iss.4, 2006-04, pp. : 339-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Psychosis in Parkinson’s Disease: Safety Considerations

By Fernandez H.H.   Trieschmann M.E.   Friedman J.H.  

Drug Safety, Vol. 26, Iss. 9, 2003-01 ,pp. : 643-659

Adis International

Access to resources Recommend Favorite

Cerebrovascular Profile Assessment in Parkinson’s Disease Patients

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 4, 2014-06 ,pp. : 712-717

Bentham Science Publishers

Access to resources Recommend Favorite

Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine

By Suh D-C.  

Drugs & Aging, Vol. 21, Iss. 6, 2004-01 ,pp. : 395-403

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

By Kaakkola S.  

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite

Subcutaneous Apomorphine: An Evidence-Based Review of its Use in Parkinson’s Disease

By Dirk Deleu  

Drugs & Aging, Vol. 21, Iss. 11, 2004-01 ,pp. : 687-709

Adis International

Access to resources Recommend Favorite